EOquin (apaziquone for intravesical instillation) is a drug currently being developed for the treatment of non-invasive bladder cancer, which is a cancer that has invaded the lining of the bladder. EOquin, an anti-cancer agent that becomes activated by reductase enzymes found in cancer cells, is formulated for administration directly into the urinary bladder. In a Phase 2 pilot study which was completed earlier this year, EOquin instilled into the bladder following surgery was well tolerated and was not absorbed in any detectable amount from the bladder wall into the bloodstream and therefore, is expected to carry a low risk of systemic toxicity, if any.
Spectrum Pharmaceuticals completed a multi-center, Phase 2 clinical trial in Europe. The results of the trial showed that EOquin was well-tolerated and produced a 67% CR (complete response) in patients, many of whom had been treated multiple times. The data from this study were presented to the FDA in early 2006.
About Bladder Cancer
The American Cancer Society estimates that 67,160 new cases of bladder
cancer will be found in the United States. According to Globocan Data
estimates, approximately 147,000 new patients will be diagnosed with
bladder cancer in Europe during 2007. The American Cancer Society estimates
that approximately 13,750 people will die of this disease in the U.S. in
2007. Globocan Data estimates more than 53,000 will die in Europe in 2007.
According to these sources, at any given time, it is estimated that there
are more than 500,000 patients in the U.S. and more than 935 thousand
patients in Europe. Non-invasive bladder cancer accounts for 75 to 80
percent of all cases of bladder cancer at first diagnosis. According to
Botteman et al., (PharmacoEconomics 2003), bladder cancer is the fifth most
expensive cancer to treat. The initial treatment of this cancer is surgical
removal of the tumor. Because of the high frequency of early rec
|SOURCE Spectrum Pharmaceuticals, Inc.|
Copyright©2007 PR Newswire.
All rights reserved